Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy

Clinical trial NCT00083720 · COMPLETED

Trial details

NCT number: NCT00083720
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Colorectal Neoplasms Metastases Neoplasm

Start date: 2004-10-01
Primary completion: 2008-04-01
Enrollment: 87

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.